



## Syndax to Announce Fourth Quarter and Year-end 2022 Financial Results and Host Conference Call and Webcast on February 28, 2023

February 21, 2023

WALTHAM, Mass., Feb. 21, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its fourth quarter and year-end 2022 financial results and provide a business update on Tuesday, February 28, after the close of the U.S. financial markets.

In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Tuesday, February 28, 2023 to discuss the Company's financial results and provide a business update.

The live audio webcast and accompanying slides may be accessed through the [Events & Presentations page](#) in the Investors section of the Company's website. Alternatively, the conference call may be accessed through the following:

Conference ID: SNDXQ422

Domestic Dial-in Number: 800-245-3047

International Dial-in Number: 203-518-9765

Live webcast: <https://www.veracast.com/webcasts/OpenEx/General/SNDXQ4.cfm>

For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website at [www.syndax.com](http://www.syndax.com) approximately 24 hours after the conference call and will be available for 90 days following the call.


### About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective inhibitor of the Menin-KMT2A binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, both currently in pivotal trials. For more information, please visit [www.syndax.com](http://www.syndax.com) or follow the Company on [Twitter](#) and [LinkedIn](#).

### Syndax Contact

Sharon Klahre  
Syndax Pharmaceuticals, Inc.  
[sklahre@syndax.com](mailto:sklahre@syndax.com)  
Tel 781.684.9827

SNDX-G

 View original content: <https://www.prnewswire.com/news-releases/syndax-to-announce-fourth-quarter-and-year-end-2022-financial-results-and-host-conference-call-and-webcast-on-february-28-2023-301751211.html>

SOURCE Syndax Pharmaceuticals, Inc.